Eva-Maria Zebedin-Brandl

Title: Eva-Maria Zebedin-Brandl: Innovator in Hematopoietic Stem Cell Research

Introduction

Eva-Maria Zebedin-Brandl is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of hematopoietic stem cell research, holding two patents that focus on enhancing the efficacy of stem cell transplantation. Her work is pivotal in improving outcomes for patients undergoing such procedures.

Latest Patents

Eva-Maria's latest patents include a composition for use in increasing engraftment efficacy of hematopoietic stem cells after transplantation. This invention provides a new use of a composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) to enhance the migration and homing of hematopoietic progenitor cells in recipients of stem cell transplants. Additionally, she has developed a method for enhancing the engraftment of hematopoietic stem cells through an ex-vivo pretreatment process. This method involves obtaining a sample containing hematopoietic stem cells, admixing a prostacyclin analog, and incubating the mixture to stimulate G alphas-signaling in the cells.

Career Highlights

Throughout her career, Eva-Maria has worked with notable companies such as Scipharm Sarl and Scipharm Sàrl. Her innovative approaches and research have positioned her as a key figure in her field, contributing to advancements in stem cell therapies.

Collaborations

Eva-Maria has collaborated with esteemed colleagues, including Michael Freissmuth and Christian Bergmayr. These partnerships have further enriched her research and development efforts in hematopoietic stem cell applications.

Conclusion

Eva-Maria Zebedin-Brandl is a trailblazer in the realm of hematopoietic stem cell research, with her patents reflecting her commitment to improving patient outcomes. Her innovative work continues to influence the field significantly.